Jobs filters
CLERICAL SPECIALIST III-OC - 10031436
Irvine, CACLERICAL SPECIALIST III-OC - 10031437
Irvine, CAPHYSICIAN RELATIONS LIAISON (PART-TIME) - 10031719
Irvine, CAPHYSICIAN ASSISTANT - INPATIENT SURGICAL ONCOLOGY - 10029858
Irvine, CAMEDICAL ASSISTANT II - 10031779
Duarte, CAEEG TECHNICIAN II - 10031780
Duarte, CAPHYSICIAN ASSISTANT - SURGICAL ONCOLOGY - 10031782
Duarte, CANURSE COORDINATOR - SUPPORTIVE CARE - 10031422
Irvine, CAADMINISTRATIVE FELLOW - OC - 10031716
Irvine, CADIRECTOR OF RESEARCH/SENIOR PHYSICIAN SCIENTIST, CHERNG FAMILY CENTER FOR INTEGRATIVE ONCOLOGY - 10031724
Duarte, CAUNIT AMBASSADOR - 10030905
Irvine, CALEAD FINANCIAL ANALYST- RVUS - 10031696
Irwindale, CA
DIRECTOR OF RESEARCH/SENIOR PHYSICIAN SCIENTIST, CHERNG FAMILY CENTER FOR INTEGRATIVE ONCOLOGY - 10031724
Duarte, CACity of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases.
Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a wholly owned subsidiary, was launched in 2019 and is dedicated to serving employers and their health care partners by providing access to City of Hope’s exceptional cancer expertise.
A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report and received Magnet Recognition from the American Nurses Credentialing Center. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona.
Director of Research Cherng Family Center for Integrative Oncology Southern California, CA
City of Hope, one of the largest and most advanced cancer research and treatment organizations in the U.S. and ranked among the nation’s Top 10 cancer centers by U.S. News & World Report, is committed to becoming a world leader in integrative oncology through the Cherng Family Center for Integrative Oncology, established with the generous support from the Panda Charitable Family Foundation. The Cherng Family Center for Integrative Oncology seeks a Director for Research to spearhead the advancement of integrative oncology research across City of Hope.
This position is a rare opportunity to work in a 500 member integrated, multidisciplinary Medical Group Practice serving an NCI designated comprehensive cancer center in Southern California and across City of Hope enterprise including Chicago, Atlanta and Phoenix. City of Hope is an expanding institution in both numbers of patients per year as well as infrastructure investment in clinical, academic and research facilities.
HIGHLIGHTS / PRIMARY RESPONSIBILITIES
This leadership role is vital to driving innovation in evidence-based integrative therapies, enhancing patient outcomes, leading to changing the standard of care and positioning the Cherng Family Center as a national and global leader. The Director of Research will function as a leader, innovator, facilitator, and change agent in advancing high-impact research initiatives and groundbreaking discoveries. They will engage integrative oncology researchers at every level (principal investigators, postdoctoral researchers, graduate students, staff researchers, etc.) as well as clinicians and stakeholders to foster collaborations. This role will be key in cultivating the next generation of integrative oncology researchers and will lead integrative oncology research efforts at City of Hope towards the greatest potential impact.
QUALIFICATIONS
· Mid-career or senior Ph.D., M.D./Ph.D. candidates welcome to apply who is an accomplished researched and leader in integrative oncology and is highly adept in clinical trials and programmatic management.
· Strong track record of research funding from NIH and other federal and non-federal sources
· The selected candidate for the position must be eligible to obtain or already hold an active California medical license
· Board certification/eligibility
PAY & BENEFITS
Base Salary Range: $400,000 - $500,000 (base pay commensurate with qualified academic rank).
o The salary range listed is exclusively for base compensation for full-time employment and does not include incentive compensation or benefits. Actual compensation will be adjusted for experience, training, hospital/community need and other factors.
Benefits information:City of Hope Medical Group Benefits
City of Hope is an equal opportunity employer.
About City of Hope
City of Hope's mission is to make hope a reality for all touched by cancer and diabetes. Founded in 1913, City of Hope has grown into one of the largest and most advanced cancer research and treatment organizations in the U.S., and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines, as well as human synthetic insulin and monoclonal antibodies. With an independent, National Cancer Institute-designated comprehensive cancer center that is ranked top 10 in the nation for cancer care by U.S. News & World Report. At its core, City of Hope’s uniquely integrated model spans cancer care, research and development, academics and training, and a broad philanthropy program that powers its work. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and cancer treatment centers and outpatient facilities in the Atlanta, Chicago and Phoenix areas. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHopeTM. For more information about City of Hope, follow us on Facebook, X, YouTube, Instagram and LinkedIn.